Ozempic vs. Mounjaro: How the Two Most Popular GLP-1 Medications Compare

Ozempic and Mounjaro are the two most prescribed GLP-1-based medications in the United States, and for good reason. Both produce meaningful blood sugar reductions and substantial weight loss. But they are not the same drug, and the differences between them — in mechanism, efficacy, side effects, and availability — matter when choosing between them.

This article compares them on the merits, using clinical trial data and FDA-approved prescribing information. It is worth noting up front that there is no single large, randomized, head-to-head trial directly comparing semaglutide (Ozempic) to tirzepatide (Mounjaro) at their respective maximum doses. Much of the comparison relies on cross-trial analysis, which has inherent limitations. Still, the available evidence paints a reasonably clear picture.

The Basics

The most significant difference is pharmacological. Ozempic activates only GLP-1 receptors. Mounjaro activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Whether this dual mechanism is the primary reason for Mounjaro's superior efficacy, or whether other molecular characteristics contribute, is still being investigated. But the clinical results consistently favor tirzepatide on the endpoints that matter most.

Blood Sugar Control

Both medications produce A1C reductions that are among the best available for type 2 diabetes. But tirzepatide has the edge.

In the SURPASS-2 trial, published in the New England Journal of Medicine in 2021, tirzepatide was directly compared to semaglutide 1 mg (not the maximum 2 mg dose of Ozempic) in patients with type 2 diabetes. At 40 weeks:

• Tirzepatide 5 mg reduced A1C by 2.01% (vs. 1.86% for semaglutide 1 mg)
• Tirzepatide 10 mg reduced A1C by 2.24%
• Tirzepatide 15 mg reduced A1C by 2.30%

All three tirzepatide doses were statistically superior to semaglutide 1 mg for A1C reduction. The difference was most pronounced at the higher doses. The SUSTAIN trials showed that Ozempic at 2 mg reduces A1C by approximately 1.5 to 1.8 percent, which is still excellent — but it does not reach the 2.0 to 2.5 percent reductions seen with tirzepatide at 10 and 15 mg.

From a practical standpoint, both medications bring most patients with moderately elevated A1C into the target range. The advantage of tirzepatide becomes more apparent in patients with very high baseline A1C (above 9 or 10 percent), where the additional glucose-lowering potency can make a meaningful clinical difference.

Weight Loss

This is where the gap between the two drugs is most visible.

In the SURPASS-2 head-to-head trial:

• Semaglutide 1 mg: -5.7 kg (-12.6 lbs)
• Tirzepatide 5 mg: -7.6 kg (-16.8 lbs)
• Tirzepatide 10 mg: -9.3 kg (-20.5 lbs)
• Tirzepatide 15 mg: -11.2 kg (-24.7 lbs)

Again, this compared tirzepatide to semaglutide at 1 mg rather than 2 mg. But even accounting for the higher Ozempic dose, the overall trial landscape favors tirzepatide. The SURMOUNT-1 trial showed tirzepatide 15 mg producing 22.5 percent body weight loss in patients without diabetes, while STEP 1 showed semaglutide 2.4 mg (the Wegovy dose, higher than any Ozempic dose) producing 14.9 percent loss in a comparable population.

The difference is roughly 7 to 8 percentage points of body weight. For a 220-pound patient, that is approximately 15 to 18 additional pounds lost with tirzepatide. This is a clinically significant gap, and it appears to be real rather than an artifact of trial design differences.

Cardiovascular Outcomes

Semaglutide currently has a major advantage in one area: proven cardiovascular benefit.

The SELECT trial, published in the New England Journal of Medicine in December 2023, demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20 percent in patients with obesity and established cardiovascular disease but without diabetes. This was a landmark result — the first time a weight loss medication demonstrated a reduction in cardiovascular mortality.

Tirzepatide does not yet have an equivalent outcome. The SURPASS-CVOT trial, Eli Lilly's cardiovascular outcomes trial for tirzepatide, is ongoing with results expected in 2027. Until those data are available, semaglutide has a stronger evidence base for patients whose primary concern is reducing cardiovascular risk.

This distinction matters clinically. For a patient with type 2 diabetes and a history of heart disease, the cardiovascular data supporting semaglutide may tip the balance, even if tirzepatide offers greater weight loss. For a patient primarily seeking weight reduction without significant cardiovascular history, the calculus may be different.

Side Effects: How They Compare

The side effect profiles are similar in character but differ in degree. Both cause gastrointestinal symptoms — nausea, vomiting, diarrhea, constipation. These are the most common reasons patients discontinue either medication.

From the SURPASS-2 head-to-head data:

At comparable doses (semaglutide 1 mg vs. tirzepatide 5 mg), tirzepatide appears slightly better tolerated. At the highest tirzepatide dose (15 mg), GI side effects are roughly comparable to semaglutide 1 mg — though tirzepatide 15 mg is producing substantially more weight loss and glucose reduction. The discontinuation rate due to adverse events was somewhat higher at tirzepatide 15 mg (7.4 percent) than semaglutide 1 mg (4.1 percent), but the higher-dose tirzepatide arms were also achieving much greater metabolic effects.

Neither medication clearly "wins" on tolerability. The clinical approach with both is the same: start low, titrate slowly, manage symptoms as they arise.

Availability and Supply

Both Ozempic and Mounjaro have experienced significant supply constraints since 2022. The demand for these medications — driven in part by off-label weight loss use — has consistently outstripped manufacturing capacity.

As of early 2026, supply has improved but intermittent shortages persist, particularly for specific dose strengths. Novo Nordisk has invested over $6 billion in manufacturing expansion, and Eli Lilly has committed similar resources. Availability varies by pharmacy and region. Patients switching between dose strengths during titration have been particularly affected, and some have experienced treatment interruptions.

From a practical standpoint, availability should be discussed with your prescriber before starting either medication. Having a plan for potential supply disruptions — including knowing whether your pharmacy can source alternative dose strengths — is prudent.

Cost Comparison

The list prices are similar (roughly $935 to $1,023 per month), and neither is affordable without insurance or manufacturer assistance. Both companies offer savings programs:

• Novo Nordisk (Ozempic): Savings card can reduce copay to as low as $25/month for commercially insured patients.
• Eli Lilly (Mounjaro): Savings card can reduce copay to as low as $25/month for commercially insured patients. Lilly has also introduced LillyDirect, a direct-to-consumer platform that offers Zepbound (the weight loss version of tirzepatide) starting at $399/month for single-dose vials without insurance.

Insurance formulary placement varies by plan. Some insurers prefer one over the other based on rebate negotiations. Prior authorization is required for both in most cases. For patients with type 2 diabetes, both are generally covered by commercial plans. For weight loss (Wegovy or Zepbound), coverage remains inconsistent.

So Which One Is Better?

There is no single correct answer, and anyone who tells you otherwise is oversimplifying.

If your primary goal is maximum weight loss and blood sugar reduction, the clinical trial data favors tirzepatide (Mounjaro/Zepbound). The weight loss advantage is consistent and clinically meaningful.

If you have established cardiovascular disease and want a medication with proven ability to reduce heart attack and stroke risk, semaglutide (Ozempic/Wegovy) has the stronger evidence base — at least until the tirzepatide cardiovascular outcomes trial reports in 2027.

If you have tried one and cannot tolerate the side effects, switching to the other is a reasonable strategy. Their side effect profiles overlap but are not identical, and some patients who struggle with semaglutide do well on tirzepatide, and vice versa.

If cost is the deciding factor, the differences are marginal at list price. Insurance coverage and savings card eligibility are more likely to determine your out-of-pocket expense than the list price difference between the two.

Ultimately, this is a conversation between you and your physician. Both medications represent a genuine advance in the treatment of type 2 diabetes and obesity. The evidence for both is strong. The question is which profile of benefits and risks best fits your specific clinical situation.